Unknown

Dataset Information

Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort.


ABSTRACT:

Purpose

Immunotherapy has emerged as a novel therapy, while many patients are refractory. Although, several biomarkers have been identified as predictive biomarkers for immunotherapy, such as tumor specific genes, PD-1/PD-L1, tumor mutation burn (TMB), and microsatellite instability (MSI), results remain unsatisfactory. The aim of this study is to evaluate the value of LRP2 mutations in predicating cancer immunotherapy.

Methods

We investigated the characteristics of low-density lipoprotein receptor-related protein 2 (LRP2) mutation in the cancer genome atlas (TCGA) and explored the potential association of LRP2 mutations with immunotherapy. Characteristics of LRP2 mutations in 33 cancer types were analyzed using large-scale public data. The association of LRP2 mutations with

SUBMITTER: Li C 

PROVIDER: S-EPMC9283634 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature